Zhejiang Wecome Pharmaceutical Company Limited is a high-tech enterprise specializing in the comprehensive processes of pharmaceutical research, development, manufacturing, and distribution within China. The company's operations encompass both modern Western pharmaceuticals and traditional Chinese medicines. Its product portfolio includes a diverse range of items such as silver yellow drop pills, yimucao softgels, and roxithromycin softgels. These medical preparations are offered in various forms, including tablets, hard capsules, softgels, granules, and pills. Since its founding in 2000, the company, headquartered in Lishui, China, has also established a presence in the pharmaceutical retail sector through its distribution networks. Notably, the firm initiated a Phase III clinical trial for its Huangjia Ruan Gan Granules, a Class 1.1 new traditional Chinese medicine for liver fibrosis, in September 2025. The company has been listed on the Shenzhen Stock Exchange's Growth Enterprise Market since August 2020.